TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
This Quarter Return
-9.39%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$982M
AUM Growth
+$21.4M
(+2.2%)
Cap. Flow
+$169M
Cap. Flow
% of AUM
17.18%
Top 10 Holdings %
Top 10 Hldgs %
37.6%
Holding
143
New
43
Increased
40
Reduced
5
Closed
15
Top Buys
| 1 |
Dynavax Technologies
DVAX
|
$28.1M |
| 2 |
ANI Pharmaceuticals
ANIP
|
$19.1M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
$15.9M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$14.9M |
| 5 |
CRISPR Therapeutics
CRSP
|
$10.8M |
Top Sells
| 1 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$24.5M |
| 2 |
MOR
MorphoSys AG American Depositary Shares
MOR
|
$14.5M |
| 3 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
$9.44M |
| 4 |
Intellia Therapeutics
NTLA
|
$5.5M |
| 5 |
BLUE
bluebird bio
BLUE
|
$3.2M |
Sector Composition
| 1 | Healthcare | 95.92% |
| 2 | Technology | 1.53% |
| 3 | Real Estate | 0.71% |
| 4 | Communication Services | 0.66% |
| 5 | Financials | 0.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Douglas Emmett
DEI
$2.75B
| $2.28M | 0.23% |
+171,138
| New | +$2.28M |
|
77
Kura Oncology
KURA
$706M
| $2.06M | 0.21% |
100,000
| – | – |
|
78
BioAtla
BCAB
$28.4M
| $1.88M | 0.19% |
1,374,076
-100,000
| -7% | -$137K |
|
79
Coherus Oncology, Inc. Common Stock
CHRS
$152M
| $1.82M | 0.19% |
+1,050,000
| New | +$1.82M |
|
80
TG Therapeutics
TGTX
$4.98B
| $1.78M | 0.18% |
100,000
| – | – |
|
81
Seres Therapeutics
MCRB
$158M
| $1.74M | 0.18% |
120,356
+75,000
| +165% | +$1.09M |
|
|
ADAP
82
Adaptimmune Therapeutics
ADAP
$12.7M
| $1.7M | 0.17% |
1,743,619
+300,000
| +21% | +$292K |
|
83
Verastem
VSTM
$599M
| $1.61M | 0.16% |
541,514
| – | – |
|
84
Galapagos
GLPG
$2.06B
| $1.38M | 0.14% |
+55,609
| New | +$1.38M |
|
85
AbCellera Biologics
ABCL
$1.16B
| $1.37M | 0.14% |
+461,699
| New | +$1.37M |
|
|
TECX
86
Tectonic Therapeutic, Inc. Common Stock
TECX
$305M
| $1.3M | 0.13% |
79,166
+8,099
| +11% | +$133K |
|
87
Erasca
ERAS
$406M
| $1.3M | 0.13% |
550,000
+450,000
| +450% | +$1.06M |
|
88
Passage Bio
PASG
$22.7M
| $1.19M | 0.12% |
75,000
| – | – |
|
89
OmniAb
OABI
$222M
| $1.13M | 0.11% |
+300,000
| New | +$1.13M |
|
90
Quince Therapeutics
QNCX
$85.9M
| $1.13M | 0.11% |
1,500,000
-1,447,652
| -49% | -$1.09M |
|
|
ATYR
91
aTyr Pharma
ATYR
$555M
| $1.05M | 0.11% |
671,134
+200,000
| +42% | +$312K |
|
|
RVNC
92
DELISTED
Revance Therapeutics, Inc.
RVNC
| $1.03M | 0.1% |
400,000
+200,000
| +100% | +$514K |
|
93
NextCure
NXTC
$13.3M
| $959K | 0.1% |
50,250
+38,207
| +317% | +$729K |
|
94
MacroGenics
MGNX
$121M
| $930K | 0.09% |
+218,856
| New | +$930K |
|
95
C4 Therapeutics
CCCC
$186M
| $924K | 0.09% |
+200,000
| New | +$924K |
|
96
Astria Therapeutics
ATXS
$382M
| $910K | 0.09% |
+100,000
| New | +$910K |
|
97
Journey Medical
DERM
$183M
| $837K | 0.09% |
148,322
+9,697
| +7% | +$54.7K |
|
98
Relmada Therapeutics
RLMD
$44.5M
| $714K | 0.07% |
237,874
+237,492
| +62,171% | +$712K |
|
99
Tyra Biosciences
TYRA
$659M
| $675K | 0.07% |
+42,223
| New | +$675K |
|
|
EGRX
100
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $666K | 0.07% |
118,857
| – | – |
|